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Background: Observational studies can provide important information on the efficacy and safety of
antihypertensive agents in the real-life clinical setting. AdADOSE was a large observational study to assess the
effectiveness of nifedipine GITS in combination with other antihypertensive agent(s). The study was also the first to
examine the role of combination therapy with nifedipine GITS in the Middle East, Pakistan and Russia, regions that
are associated with particularly high cardiovascular risk.
Methods: AdADOSE was a 12-week, international, multicenter, prospective, observational study. Patients with
hypertension (ie, blood pressure [BP] >140/90 mm Hg, or >130/80 mm Hg in patients at high or very high cardiovascular
risk) received once-daily nifedipine GITS (30, 60 or 90 mg) in combination with another antihypertensive or as
add-on to existing therapy. The primary study endpoint was the proportion of patients who achieved the target BP
of <140/90 mm Hg (or <130/80 mm Hg for those at high or very high cardiovascular risk). Study outcomes are reported
by descriptive statistics.
Results: The study enrolled 4497 patients (n = 4477, safety population; n = 3430, efficacy population). Baseline mean
systolic/diastolic BP (SBP/DBP) was 166.4/99.7 mm Hg; 85.2 % of patients had received prior antihypertensive treatment,
and 90.6 % had ≥1 concomitant diseases. Following combination treatment with nifedipine GITS, target BP was
achieved by 64.8 % of patients without concomitant diseases, and by 56.5 %, 32.3 % and 22.6 % with 1, 2–3 and >3
concomitant diseases, respectively. The proportion of patients achieving target BP was 51.5 % in previously untreated
and 33.7 % in previously treated patients. Nifedipine GITS combination treatment provided mean SBP/DBP changes
of −36.1/−18.8 mm Hg in all patients, −40.2/−21.5 mm Hg in previously untreated patients, and −35.6/−18.4 mm Hg in
previously treated patients, with similar BP reductions irrespective of the number of concomitant diseases. Drug-related
adverse events (AEs) were reported in 2.6 % patients. There were no serious AEs and only 0.8 % of patients discontinued
due to drug-related AEs.
Conclusions: Combination therapy with nifedipine GITS in a real-life observational setting was highly effective in
reducing SBP/DBP in a range of hypertensive patients, with low rates of treatment-related AEs.
Trial registration: Trial registration: at ClinicalTrials.gov registration number NCT01118286.
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Hypertension is an established risk factor in the develop-
ment of cardiovascular (CV) disease [1]. According to
the World Health Organization, the worldwide preva-
lence of hypertension is increasing and is estimated to
cause approximately 7 million premature deaths a year
[2]. Clinical evidence supports blood pressure (BP) low-
ering to achieve defined BP targets in order to reduce
the risk of CV outcomes [3, 4]. Successful attainment of
adequate BP control through the selection of appropriate
treatment is, therefore, of great concern to physicians
and patients alike.
Several clinical trials have established the efficacy of the
calcium channel blocker (CCB) nifedipine gastrointestinal
therapeutic system (GITS), a dihydropyridine CCB, in the
treatment of hypertension [5–8]. The Intervention as
a Goal in Hypertension Treatment (INSIGHT) study
showed that once-daily dosing with nifedipine GITS effec-
tuated smooth and continuous BP control compared with
conventional first-line antihypertensive therapy in the
form of a diuretic [7]. A post hoc analysis of the INSIGHT
data using the Framingham risk equation showed that ni-
fedipine GITS improved CV outcomes and reduced the
risk of CV events by an estimated 50 % [9].
The European Society of Hypertension (ESH)/European
Society of Cardiology (ESC) guidelines recognize that
most patients with elevated BP will require a combination
of 2 or more antihypertensive drugs in order to achieve
their BP target [10]. The combination of a CCB such as
nifedipine with beta-blockers, diuretics, angiotensin-
converting enzyme (ACE) inhibitors or angiotensin II
receptor blockers (ARBs) has proven to be beneficial
[11, 12], and guidelines recommend these CCB combi-
nations as first-line treatment [10, 13, 14]. However, in
routine clinical practice, the choice of antihypertensive
agent(s) is likely to be based on the treating physician’s
clinical experience and preferences. Observational
studies can provide important information on the effi-
cacy and safety of antihypertensive agents in the real-
life clinical setting that is likely to reflect and inform
daily practice.
This large-scale observational study (AdADOSE) assessed
the effectiveness and safety of nifedipine GITS (30, 60
or 90 mg) in combination with other antihypertensive
agent(s) in a real-life setting. This is also one of the first
large-scale studies to investigate the benefits of nifedipine
GITS in antihypertensive combination therapy in regions
with high CV risk burden, including the Middle East, a
high CV risk region because it has one of the highest oc-
currences of diabetes globally [15, 16], and Russia and
Pakistan, where mortality due to CV disease is signifi-
cantly higher than in Western Europe [16–18]. The
study was performed in a large cohort of previously
treated and untreated hypertensive patients, with andwithout additional CV comorbidities, reflecting the range
of patients typically encountered by physicians.
Methods
Design
This was a 12-week, international, multicenter, prospect-
ive, observational phase IV study to monitor the effective-
ness and safety of antihypertensive therapy comprising
once-daily nifedipine GITS at doses of 30, 60 or 90 mg in
combination with any other antihypertensive agent(s) in
hypertensive patients (ClinicalTrials.gov registration
number NCT01118286). Patients were enrolled from
318 clinical practices in 10 countries (Bahrain, Egypt,
Jordan, Lebanon, Oman, Pakistan, Qatar, Russia, Saudi
Arabia and United Arab Emirates) between January
2010 and September 2011.
Patients attended an initial visit and up to 3 follow-up
clinic visits during the 12-week observation period. The
timing of visits was not prespecified, but was in accord-
ance with the treating physician’s normal practice. The
decision to prescribe once-daily 30- or 60-mg nifedipine
GITS tablets and to up-titrate to a dose of 90 mg or to
down-titrate from a higher dose to 30 mg was made by
the treating physician. The study was conducted using
approved country-specific prescribing information for
the study drugs. It was also performed in accordance
with the guidelines of the European Medicines Agency
and the US Food and Drug Administration, and was
conducted in accordance with the Declaration of
Helsinki (1996) and the ICH Harmonised Tripartite
Guideline for Good Clinical Practice (GCP). Ethics com-
mittee approval for this study was provided in Pakistan
by the Research Ethics Committee of the Ministry of
Health, and in Russia by the Ethics Committee of the
Federal Service on Surveillance in Healthcare and Social
Development. No ethics committee approval was re-
quired in Bahrain, Egypt, Jordan, Lebanon, Oman, Qatar,
Saudi Arabia and the United Arab Emirates at the time
of study conduct.
Written informed consent (in accordance with GCP
and local legislation) was provided by all patients prior
to any study-specific investigations.
Patients
Male or female patients aged ≥18 years with essential
hypertension (ie, BP >140/90 mm Hg or >130/80 mm
Hg in patients at high or very high CV risk) [10] were
eligible for enrollment. Patients could be either previ-
ously untreated or insufficiently controlled on current
antihypertensive regimens not containing CCBs. Patients
with contraindications to nifedipine GITS (as stated in
the local product information) were not considered suit-
able for nifedipine GITS treatment by the treating phys-
ician and were, therefore, excluded.
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This study had the primary aim to assess the proportion
of patients reaching the target BP of <140/90 mm Hg
(or <130/80 mm Hg for those at high or very high CV
risk), in accordance with ESH/ESC guidelines current at
the time of study [10]. Systolic BP (SBP), diastolic BP
(DBP), pulse pressure and heart rate were measured at
the initial study visit and at the follow-up visits using
standard cuff BP measuring equipment, according to
local practice. A single BP measurement was the stand-
ard approach in the participating countries, with the ex-
ception of Egypt, where a mean of 3 measurements
taken a few minutes apart was used. Achievement of tar-
get BP in this manuscript is a composite of the propor-
tion of patients not at high/very high CV risk achieving
their BP target of <140/90 mm Hg and the proportion of
patients at high/very high CV risk achieving their BP tar-
get of <130/80 mm Hg.
All adverse events (AEs) that occurred throughout the
study period were recorded. AEs were classified using the
Medical Dictionary for Regulatory Activities (MedDRA)
version 14.1, and were evaluated for seriousness, relation
to study drug, action taken and outcomes.
Efficacy and tolerability were also evaluated in the phy-
sician’s final assessment of therapy. All data were re-
corded in standardized case report forms.
Statistical analyses
Descriptive summary statistics for categorical and quan-
titative (continuous) data were reported. Percentage
values were calculated as the proportion of each cat-
egory including the category of missing values. Analyses
were also stratified according to age, sex, pretreatment
status, initial BP and concomitant diseases and these
data were used for the CV risk stratification of the pa-
tients. Primary safety analyses were performed on the
full analysis set, which consisted of all enrolled patients
who took any dose of study medication in combination
with any other antihypertensive agent(s) (except CCBs)
who had an initial BP measurement and at least 1
follow-up BP measurement. The efficacy evaluation was
performed on all patients with at least 1 follow-up BP
measurement.
Results
Patient disposition and baseline characteristics
A total of 4497 patients were enrolled in the study, and
4477 (99.6 %) were included in the safety analysis. Of
these 4477 patients, 1047 (23.4 %) patients were ex-
cluded since they had received nifedipine GITS as a
monotherapy only, leaving 3430 (76.6 %) evaluable for
the efficacy analysis. The reasons for study exclusions
are summarized in Fig. 1. Baseline characteristics for the
efficacy population are presented in Table 1. Patientswere enrolled from Egypt (n = 939), Pakistan (n = 749),
Saudi Arabia (n = 650), Russia (n = 461), Lebanon (n =
229), United Arab Emirates (n = 127), Qatar (n = 96),
Jordan (n = 85), Bahrain (n = 61), and Oman (n = 33).
At the initial visit, 2097/3430 (61.1 %) patients were
classified as being at high or very high CV risk [10].
General concomitant diseases/conditions were reported
in 92.3 % of the patients and specific CV concomitant
diseases/conditions in 90.6 % patients, including dyslip-
idemia (41.3 %), obesity (26.7 %) and fatty liver (26.7 %)
(Table 2). A total of 2922/3430 (85.2 %) patients had re-
ceived previous antihypertensive treatment.
2427/3430 (70.8 %) patients attended 4 clinic visits,
660 (19.2 %) attended 3 and 341 (9.9 %) attended 2 visits
during the study. For 2 (0.1 %) patients, the date(s) for
the follow-up visit(s) were missing. However, these 2 pa-
tients were included in the efficacy analyses, as there
was a final assessment at the end of the observation
period. The average time between visits was approxi-
mately 4 weeks.
Treatment
The majority of patients (2073/3430 [60.4 %]) received a
constant daily dose of 30-mg nifedipine GITS during the
study period; another 686 (20.0 %) patients received a
constant daily dose of 60-mg nifedipine GITS, and 392
(11.4 %) had their daily dose adjusted from 30-mg to 60-
mg nifedipine GITS during the study period. Doses were
down-titrated to 30-mg nifedipine GITS in 97 patients
(2.9 %). Nine (0.3 %) patients completed the study taking
90-mg nifedipine GITS.
Details on the concomitant drugs prescribed by physi-
cians were also recorded at visits. At the initial visit,
most patients were taking 1 (1792 [52.2 %]) or 2 (1053
[30.7 %]) concomitant antihypertensive drugs, while 369
(10.8 %) and 55 (1.6 %), respectively, took 3 or 4 con-
comitant antihypertensive drugs, and 9 patients (<0.3 %)
took 5 or 6 concomitant antihypertensive drugs. 152 pa-
tients (4.4 %) took no concomitant antihypertensive drug
at the study start but did so during the observation
period, and were therefore included in the analysis. At
the last visit, the proportion of patients taking 1 con-
comitant antihypertensive drug had fallen to 49.8 %
(1707) whereas the proportion taking no additional anti-
hypertensive drug increased to 7.0 % (240). The latter
patients were also included in the efficacy analysis since
they were prescribed antihypertensive combination ther-
apy at some point during the study period.
Selection of other antihypertensive medications (and
doses) was also at the discretion of the treating physician,
and reflected daily practice. While assessment of comedi-
cation use was not a primary objective of the study, the
most frequently reported concomitant antihypertensive
drugs at both initial and final visits were beta-blockers
Fig. 1 Study design. Disposition of patients treated with nifedipine GITS once daily as part of combination antihypertensive treatment regimens.
GITS = gastrointestinal therapeutic system; NIF = nifedipine GITS. Note: * Information on exclusions overlaps
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by ACE inhibitors (32.2 % and 31.5 %) and thiazide
diuretics (31.0 % and 30.3 %). The most frequent non-
antihypertensive concomitant medications were acetyl-
salicylic acid (28.3 % of patients), atorvastatin calcium
(13.8 %) and metformin (11.4 %).
Efficacy
Overall, the target BP goal was reached by 36.3 % (1246/
3428) of patients treated with nifedipine GITS combination
therapy. The proportion of patients not at high/very high
CV risk who achieved the target BP of <140/90 mm Hg
was 70.8 % (942/1331), whereas the proportion of patients
at high or very high risk who achieved the lower BP target
of 130/80 mm Hg was only 14.5 %. When patients who
met the target BP (ie, <140/90 mm Hg, or <130/80 mm Hg
in those at high or very high CV risk) were stratified ac-
cording to specific CV concomitant diseases, the respective
target BP was achieved by 64.8 % in patients with no con-
comitant disease, and by 56.5 %, 32.3 % and 22.6 % with 1,
2 or 3 and >3 concomitant diseases, respectively (Table 3).
The BP target was achieved in 51.5 % of patients who were
previously untreated and in 33.7 % of those who had previ-
ously received antihypertensive medication (Table 3).Combination therapy with nifedipine GITS provided
a mean absolute reduction in SBP/DBP of −36.1/–18.8 mm
Hg (Fig. 2). BP reductions were similar irrespective of
the number of concomitant diseases present, with mean
SBP reductions ranging from 35.3 to 38.8 mm Hg, and
mean DBP reductions ranging from 18.3 to 19.5 mm
Hg during the study (Fig. 2). Mean absolute reductions
were −40.2/−21.5 mm Hg in previously untreated
and −35.6/−18.4 mm Hg in previously treated patients.
When patients were stratified according to initial BP
values, mean BP reductions were greater for higher
baseline SBP (Fig. 3a) and DBP (Fig. 3b). In addition,
time course analyses showed that rates of systolic
hypertension (ie, SBP ≥140 mm Hg) decreased steadily
during study from 97.8 % at initial visit to 22.8 % by the
last visit, as did diastolic hypertension (ie, DBP ≥90 mm
Hg; from 92.6 to 13.0 %). The decreases in rates of
systolic and diastolic hypertension during the study
occurred in both previously treated and untreated
patients (Table 4). Isolated systolic hypertension (ie, ≥140/
<90 mm Hg) was recorded in 6.4 % (218) of patients at
the initial visit; this increased to 20.0 % (686) by the
first follow-up visit and then decreased to 14.4 % (493)
by the last visit.
Table 1 Patient baseline characteristics, efficacy population
Characteristic n (%)




Mean age, years ± SD (range); n = 3322 53.4 ± 10.4 (19.0–89.0)
Age, n (%)
<65 years 2836 (82.7)






Mean BMI, kg/m2 ± SD (range); n = 3214 29.9 ± 5.2 (15.1–57.4)
Mean BP, mm Hg ± SD (range)
SBP [n = 3413] 166.4 ± 16.7 (100.0–260.0)
DBP [n = 3418] 99.7 ± 9.9 (55.0–170.0)
Stages of hypertension, n (%)a
Normal 8 (0.2)
High normal 16 (0.5)
Grade 1 (mild) 407 (11.9)
Grade 2 (moderate) 1620 (47.2)
Grade 3 (severe) 1142 (33.3)
Isolated systolic hypertension 218 (6.4)
Duration of hypertension, n (%); n = 3426
Newly diagnosed 479 (14.0)
Previously diagnosed 2947 (85.9)
<1 year 434 (14.7)
1–5 years 1210 (41.1)
6–10 years 692 (23.5)
>10 years 554 (18.8)





Previous classes of antihypertensive therapy,
n (%); n = 2922b




Thiazide diuretics 940 (32.2)
Other 97 (3.3)
Table 1 Patient baseline characteristics, efficacy population
(Continued)
Smoking history, n (%)
Current smoker 725 (21.1)
Never 1940 (56.6)
Past smoker 606 (17.7)
Data for all variables were not available for all patients
ACE angiotensin-converting enzyme, ARBs angiotensin II receptor blockers, BMI
body mass index, CCBs calcium channel blockers, DBP diastolic blood pressure,
GITS gastrointestinal therapeutic system, SBP systolic blood pressure, SD
standard deviation
aDefinitions according to ESH/ESC 2007 guidelines. bMultiple responses
possible. cOther than nifedipine GITS
Table 2 Specific concomitant diseases at baseline
Patients (n = 3430)
Patients with specific concomitant diseases, n (%) 3109 (90.6)
Dyslipidemia 1417 (41.3)
Obesity 917 (26.7)
Fatty liver 917 (26.7)
Stable angina pectoris 445 (13.0)
Diabetic neuropathy 396 (11.5)
Microalbuminuria 275 (8.0)
Diabetic retinopathy 271 (7.9)
Myocardial infarction 230 (6.7)
Renal insufficiency 167 (4.9)
Peripheral vascular disease 158 (4.6)
Congestive heart failure 141 (4.1)
Coronary revascularization 137 (4.0)
Transient ischemic attack 115 (3.4)
Cerebrovascular accident 97 (2.8)












aCoded according to Medical Dictionary for Regulatory Activities System
Organ Class
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Table 3 Blood pressure goal
Patients reaching BP goal, n (%)
1st follow-up visit Last visit
Overall population; n = 3428a 542 (15.8) 1246 (36.3)
Previous antihypertensive medication
No; n = 421 86 (20.4) 217 (51.5)
Yes; n = 2920 431 (14.8) 985 (33.7)
Concomitant disease
0; n = 264 82 (31.1) 171 (64.8)
1; n = 621 177 (28.5) 351 (56.5)
2–3; n = 1547 213 (13.8) 499 (32.3)
>3; n = 996 70 (7.0) 225 (22.6)
Proportion of patients reaching target BP following treatment with nifedipine
GITS in combination with other antihypertensive agents
BP blood pressure, GITS gastrointestinal therapeutic system
aBP <140/90 mm Hg (or BP <130/80 mm Hg in those at high or very high
CV risk)
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(± SD) decreased from 66.7 ± 14.9 mm Hg to 49.3 ±
9.3 mm Hg, and the mean heart rate (± SD) decreased
from 78.6 ± 10.8 bpm to 75.5 ± 7.7 bpm. Changes in these
parameters were similar for patients regardless of the use
of previous antihypertensive medication. In patients who
had not previously received antihypertensive medication,
mean pulse pressure decreased from 67.3 ± 15.1 mm Hg to
48.4 ± 8.7 mm Hg, and mean heart rate decreased from
81.8 ± 9.5 bpm to 76.4 ± 7.5 bpm. In patients previously
treated with antihypertensive medication, mean pulse pres-
sure decreased from 66.6 ± 14.8 mm Hg to 49.4 ± 9.4 mmFig. 2 Change in SBP and DBP. Mean absolute difference in SBP and DBP i
medication and according to number of concomitant diseases (initial to las
as part of combination antihypertensive regimens. DBP = diastolic blood pr
blood pressureHg, and mean heart rate decreased slightly from 78.0 ±
10.9 bpm to 75.4 ± 7.8 bpm.
Tolerability
A total of 142/4477 (3.17 %) patients experienced 201
AEs during the study period. The most common AEs
were peripheral edema (54 patients [1.2 %]) and head-
ache (28 [0.6 %]) (Table 5). Overall, 166 events in 114/
4477 (2.6 %) patients were considered by the treating
physician to be study-drug related, including peripheral
edema (48 patients [1.1 %]) and headache (26 [0.6 %]).
No serious AEs or serious study-drug–related AEs were
reported. Forty-eight AEs in 35 (0.8 %) patients resulted
in permanent discontinuation of study drug; peripheral
edema (14 [0.3 %]) was the most common AE leading to
treatment discontinuation.
Physician satisfaction with nifedipine GITS combination
treatment
Treating physicians assessed the efficacy of nifedipine GITS
combination treatment as “very good” in 64.2 % (2203/
3430) of patients, “good” in 30.2 % (1036), “sufficient” in
3.9 % (133) and “insufficient” in 1.1 % (38), with missing
data in the remainder. The tolerability of nifedipine GITS
combination treatment was assessed as “very good” in
58.0 % (1991), “good” in 35.7 % (1224), “sufficient” in 3.3 %
(112) and “insufficient” in 0.8 % (29), with missing data in
the remainder. Overall, treating physicians were “very
satisfied” in 57.7 % (1978) and “satisfied” in 38.2 % (1311)
of patients with the therapeutic effect of nifedipine GITS
combination treatment; 1.7 % (58) were “unsatisfied” andn patients who had or had not previously received antihypertensive
t visit) following 12 weeks’ treatment with nifedipine GITS once daily
essure; GITS = gastrointestinal therapeutic system; SBP = systolic
Fig. 3 Change in SBP and DBP. Mean absolute difference in SBP (a) and DBP (b) according to baseline SBP and DBP following 12 weeks’
treatment (initial to last visit) with nifedipine GITS once daily as part of combination antihypertensive regimens. DBP = diastolic blood pressure;
GITS = gastrointestinal therapeutic system; SBP = systolic blood pressure
Table 4 Systolic and diastolic hypertension
SBP <140 mm Hg DBP <90 mm Hg
Initial visit Last visit Initial visit Last visit
Overall population, n (%); n = 3430 60 (1.7) 2644 (77.1) 242 (7.1) 2975 (86.8)
No previous antihypertensive medication, n (%); n = 421 4 (1.0) 343 (81.5) 10 (2.4) 368 (87.4)
Previously received antihypertensive medication, n (%); n = 2922 50 (1.7) 2238 (76.6) 220 (7.5) 2539 (87.0)
Proportion of patients with SBP <140 mm Hg or DBP <90 mm Hg following treatment with nifedipine GITS in combination with other antihypertensive agents
DBP diastolic blood pressure, GITS gastrointestinal therapeutic system, SBP systolic blood pressure
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Table 5 AEs and drug-related AEs
AEs Drug-related AEs
Total, patients (%); n = 4477 142 (3.2) 114 (2.6)
Peripheral edema, n (%) 54 (1.2) 48 (1.1)
Headache, n (%) 28 (0.6) 26 (0.6)
Edema, n (%) 15 (0.3) 9 (0.2)
Palpitations, n (%) 11 (0.3) 9 (0.2)
Flushing, n (%) 10 (0.2) 10 (0.2)
Constipation, n (%) 5 (0.1) 5 (0.1)
Dizziness, n (%) 5 (0.1) 5 (0.1)
Incidence of AEs and drug-related AEs (≥0.1 % incidence) in patients during
treatment with nifedipine GITS in combination with other
antihypertensive agents
AEs adverse events, GITS gastrointestinal therapeutic system
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remainder. Physicians intended to continue with nife-
dipine GITS combination treatment beyond the study
period in 93.4 % (3202) of patients.
Discussion
The aim of this observational study was to monitor the
effectiveness and safety of nifedipine GITS combination
therapy when used in routine clinical practice in coun-
tries in the Middle East, Pakistan and Russia. In this
large cohort of hypertensive patients, the majority
(85 %) had previously received antihypertensive treat-
ment, usually with 1 or 2 antihypertensive therapies;
beta-blockers (48 %) and ACE inhibitors (41 %) were the
most common medications. Despite the high level of
pretreatment, nearly one half of the patients (47 %) had
SBP 160–179 mm Hg and one-third (33 %) had SBP
≥180 mm Hg at study baseline. Many patients had add-
itional CV risk factors, leading to over one half (61 %) of
patients being classified as at high CV risk. During the
study period, the combination of nifedipine GITS with
other antihypertensive medications resulted in a mean
BP reduction of −36.1/−18.8 mm Hg in all patients. This
clinically significant reduction was consistent in patients
stratified according to baseline antihypertensive medica-
tion and irrespective of the number of concomitant dis-
eases. Greater BP reductions were observed in patients
with higher baseline BP.
A recent large-scale observational study across the Far
East, the Middle East, Pakistan and Mexico, with nifedi-
pine GITS 30 mg or 60 mg, given either as monotherapy
(51.8 % of patients) or as add-on (48.2 % of patients) to
antihypertensive therapy, reported an overall mean BP
reduction of −28/−14 mm Hg. The extent of BP reduc-
tion was associated with hypertension grade, age, pres-
ence of ≥5 additional CV risk factors, as well as prior
treatment [19]. Overall, target BP (<140/90 mm Hg;
130/80 mm Hg in patients with diabetes) was achievedin 29.5 % of patients. The BP target achievement rate
was slightly higher in those receiving nifedipine GITS as
monotherapy (33.4 %) than in those receiving nifedipine
GITS as part of an antihypertensive combination regi-
men (25.3 %), which may have been because the patients
requiring combination therapy had more severe degrees
of hypertension. Other, smaller observational studies in
China have similarly shown the BP-lowering efficacy of
nifedipine GITS [20, 21].
The findings from the present observational study
confirm that nifedipine GITS in initial combination ther-
apy or as add-on therapy improves the achievement of
BP treatment goals (based on ESH/ESC guidelines at the
time of study) in a broad spectrum of patients. In those
without additional comorbidities, an additional 34 % of
patients reached target BP (from 31 to 65 %) after
12 weeks of nifedipine GITS treatment. Nifedipine GITS
combination therapy was also effective in patients with
numerous (≥3) concomitant diseases, where the BP tar-
get achievement rate was improved by 16 % (from 7 to
23 %). The reduction in SBP and DBP observed in our
study is reflected by the substantial shifts from higher to
lower hypertension grades. The proportion of patients
with SBP <140 mm Hg or DBP <90 mm Hg increased
substantially during the study (from <2 % and 7 % at the
initial visit to 77 % and 87 %, respectively). Again, these
observations were consistent in both previously treated
and untreated patients.
A limitation of the AdADOSE study is that a stricter
treatment target was used for patients at high or very
high CV risk (<130/80 mm Hg) compared with the goal
in other patients (<140/90 mm Hg). The lower target is
notoriously difficult to achieve in clinical practice and
may not even be beneficial, as suggested by the 2009 re-
appraisal of the ESH/ESC guidelines [13]. The ESH/ESC
guidelines were updated in 2013, and now recommend a
target of <140/90 mm Hg for all patients with an opti-
mal DBP of between 80 and 85 mm Hg for diabetic pa-
tients [22]. The UK NICE guidelines also recommend a
BP target of <140/90 mm Hg for all hypertensive pa-
tients [14]. If this BP target of <140/90 mm Hg were ap-
plied to all patients in this study, irrespective of CV risk
status, the proportion of patients achieving BP control
would increase by 40 percentage points—to 72 %—with
nifedipine GITS combination therapy. This high rate of
achievement of the newer single BP target of 140/
90 mm Hg was also not affected by the presence of con-
comitant diseases, since 69.7 % of all patients without
concomitant disease would have achieved this target BP,
as well as 69.7 %, 71.6 % and 76.0 % of patients with 1,
2–3 or >3 concomitant diseases, respectively [23]. These
data demonstrate the efficacy of a nifedipine GITS-
containing combination therapy and compare favorably
with data from other studies such as the National Health
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31.0 % of the overall treated population of hypertensive pa-
tients achieved control defined as <140/90 mm Hg [24].
A further limitation of this study is the classification of
patients at high or very high CV risk. On the case report
forms used, patients with diabetes were reported as such
only if they had diabetic retinopathy or diabetic neur-
opathy, so it is likely that more patients had diabetes in
this study than were reported. Based on this, it is diffi-
cult to classify patients with confidence according to
their CV risk, and a greater emphasis has therefore been
placed in the interpretation of outcomes on the number
of concomitant diseases. Other limitations pertain to the
nature of the study design; being observational, there
was no control group, and the specific contributory ef-
fects of factors such as the types (and doses) of con-
comitant medications used, the selection of nifedipine
GITS dose (30 mg or 60 mg), and the patient ethnicity is
unknown. It should be noted that a detailed assessment
of the impact of concomitant medications was not an
objective of this observational study. Prescribing low-
dose combination therapy, rather than up-titration of
monotherapy, is in accordance with guideline recom-
mendations; however, the dose of the medication prior
to change was not recorded, and it is not possible to de-
termine if it was maximal. Additionally, the effect of po-
tential suboptimal treatment regimens is unknown,
especially in high CV risk patients. Finally, the potential
influence of “white-coat hypertension” on reported out-
comes cannot be determined in this study [25].
The profile of AEs in AdADOSE (eg, edema and head-
ache) was in agreement with the known safety profile
of nifedipine GITS. The incidence of drug-related AEs
(2.6 % of patients) was lower than expected from refer-
ence safety and tolerability information [5, 7, 19–21, 26].
This may suggest a reporting bias in the current study,
with investigators tending to underreport mild to mod-
erate AEs that are known to be associated with nifedi-
pine GITS therapy. Underreporting of mild/moderate
AEs is a recognized feature of observational studies. In
terms of treatment satisfaction, physicians rated the
overall efficacy and tolerability of nifedipine GITS as
very good or good in 94 % of patients, and they rated
their satisfaction with therapeutic efficacy as very good
or good for 96 %. For just over 93 % of patients in this
study, the physicians intended to continue antihyperten-
sive combination therapy containing nifedipine GITS.
The large observational AdADOSE study performed in
patients from countries with high CV risk burden provides
results that are relevant to real-world practice. Nifedipine
GITS 30 mg or 60 mg once daily in combination therapy
is highly effective in the treatment of hypertension, irre-
spective of the presence of concomitant disease, and is
generally well tolerated with a very low incidence of AEs.This study therefore confirms the efficacy and safety pro-
file of nifedipine GITS that was demonstrated in earlier
clinical trials and supports its value in the treatment of pa-
tients with hypertension including those with additional
CV risk factors and comorbidities. The study also high-
lights the importance of combination therapy in a real-life
setting to improve BP control rates.
Conclusion
Combination therapy with nifedipine GITS in a real-life
observational setting was highly effective in reducing SBP/
DBP in a range of hypertensive patients, with low rates of
treatment-related adverse events.
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